Healthcare / BiotechnologyHKSE
$3.88
-0.03 (-0.77%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-382.6M · quality 63.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-37.2%
↓Gross Margin
83.6%
↑Debt/Equity
0.40
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-13.0%
FCF CAGR
—
FCF margin
-169.8%
FCF / Net income
0.75x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $105.3M · net income $-239.1M · FCF $-178.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $105.3M | $105.3M | $92.0M | $67.3M | $160.1M |
| Net Income | $-239.1M | $-239.1M | $-319.3M | $-581.2M | $-601.5M |
| EBITDA | $-212.8M | $-212.8M | $-291.7M | $-550.3M | $-573.3M |
| EPS | -0.38 | -0.38 | -0.51 | -0.94 | -0.97 |
| Gross Margin | 83.6% | 83.6% | 81.9% | 81.7% | 82.4% |
| Operating Margin | -199.9% | -199.9% | -378.6% | -982.9% | -542.4% |
| Net Margin | -227.0% | -227.0% | -347.2% | -863.5% | -375.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.40 | 0.40 | 0.29 | 0.18 | 0.03 |
| Current Ratio | 2.97 | 2.97 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-178.9M | $-178.9M | $-382.6M | $-778.9M | $-671.6M |
| Returns | |||||
| ROE | -37.2% | -37.2% | -37.5% | -50.7% | -35.1% |
| Valuation | |||||
| P/B | 3.78 | 3.78 | 0.53 | 1.00 | 2.15 |
| Growth & Yield | |||||
| Revenue Growth | 14.6% | 14.6% | 36.6% | -58.0% | — |
| EPS Growth | 25.5% | 25.5% | 45.7% | 3.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+4.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.51 → -0.38
Residual
+4.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.